Vera Therapeutics Unveils New Employee Compensation Plan with Inducement Stock Options and RSUs

Reuters

08/09

Vera <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Unveils New Employee Compensation Plan with Inducement Stock Options and RSUs

BRISBANE, Calif., Aug. 08, 2025 - Vera Therapeutics, Inc. (Nasdaq: VERA) has disclosed the granting of inducement awards to eight new employees under its 2024 Inducement Plan, as approved by the company's Compensation Committee. On August 4, 2025, the awarded inducements included non-qualified stock options to purchase 99,000 shares of Class A common stock and restricted stock units (RSUs) for 48,200 shares. The stock options carry an exercise price of $20.45 per share, matching the closing trading price on the grant date, and will vest over four years. RSUs are set to vest annually over the same period, beginning on August 20, 2025. These awards are in accordance with Nasdaq Listing Rule 5635(c)(4), contingent on continued employment with Vera.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9508297-en) on August 08, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2558744435"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2558744435\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2558744435?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-09 04:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2558744435","market":"nz","top_or_hot":-1,"title":"Vera Therapeutics Unveils New Employee Compensation Plan with Inducement Stock Options and RSUs","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vera <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils New Employee Compensation Plan with Inducement Stock Options and RSUs\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BRISBANE, Calif., Aug. 08, 2025 - <a href=\"https://laohu8.com/S/VERA\">Vera Therapeutics, Inc.</a> (Nasdaq: VERA) has disclosed the granting of inducement awards to eight new employees under its 2024 Inducement Plan, as approved by the company's Compensation Committee. On August 4, 2025, the awarded inducements included non-qualified stock options to purchase 99,000 shares of Class A common stock and restricted stock units (RSUs) for 48,200 shares. The stock options carry an exercise price of $20.45 per share, matching the closing trading price on the grant date, and will vest over four years. RSUs are set to vest annually over the same period, beginning on August 20, 2025. These awards are in accordance with Nasdaq Listing Rule 5635(c)(4), contingent on continued employment with Vera.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9508297-en) on August 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vera Therapeutics Unveils New Employee Compensation Plan with Inducement Stock Options and RSUs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVera Therapeutics Unveils New Employee Compensation Plan with Inducement Stock Options and RSUs\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-09 04:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vera <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils New Employee Compensation Plan with Inducement Stock Options and RSUs\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BRISBANE, Calif., Aug. 08, 2025 - <a href=\"https://laohu8.com/S/VERA\">Vera Therapeutics, Inc.</a> (Nasdaq: VERA) has disclosed the granting of inducement awards to eight new employees under its 2024 Inducement Plan, as approved by the company's Compensation Committee. On August 4, 2025, the awarded inducements included non-qualified stock options to purchase 99,000 shares of Class A common stock and restricted stock units (RSUs) for 48,200 shares. The stock options carry an exercise price of $20.45 per share, matching the closing trading price on the grant date, and will vest over four years. RSUs are set to vest annually over the same period, beginning on August 20, 2025. These awards are in accordance with Nasdaq Listing Rule 5635(c)(4), contingent on continued employment with Vera.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9508297-en) on August 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VERA","symbol_name":"Vera Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nNDL3NTWNL:1","article_id":"2558744435","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2558744435","pubTimestamp":1754683521,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRISBANE, Calif., Aug. 08, 2025 - Vera Therapeutics, Inc.  has disclosed the granting of inducement awards to eight new employees under its 2024 Inducement Plan, as approved by the company's Compensation Committee. On August 4, 2025, the awarded inducements included non-qualified stock options to purchase 99,000 shares of Class A common stock and restricted stock units  for 48,200 shares. The stock options carry an exercise price of $20.45 per share, matching the closing trading price on the grant date, and will vest over four years. RSUs are set to vest annually over the same period, beginning on August 20, 2025. These awards are in accordance with Nasdaq Listing Rule 5635, contingent on continued employment with Vera.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financia","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VERA":"Vera Therapeutics, Inc.","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4539":"次新股","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4588":"碎股","BK4585":"ETF&股票定投概念","NDAQ":"纳斯达克OMX交易所","BK4112":"金融交易所和数据","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4139":"生物科技","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC"},"translate_title":"Vera Therapeutics推出新的员工薪酬计划，包括激励股票期权和受限制股份单位","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"VERA":0.9},"content_text":"Vera Therapeutics Unveils New Employee Compensation Plan with Inducement Stock Options and RSUs\n    \n\n        BRISBANE, Calif., Aug. 08, 2025 - Vera Therapeutics, Inc. (Nasdaq: VERA) has disclosed the granting of inducement awards to eight new employees under its 2024 Inducement Plan, as approved by the company's Compensation Committee. On August 4, 2025, the awarded inducements included non-qualified stock options to purchase 99,000 shares of Class A common stock and restricted stock units (RSUs) for 48,200 shares. The stock options carry an exercise price of $20.45 per share, matching the closing trading price on the grant date, and will vest over four years. RSUs are set to vest annually over the same period, beginning on August 20, 2025. These awards are in accordance with Nasdaq Listing Rule 5635(c)(4), contingent on continued employment with Vera.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9508297-en) on August 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}